HESTAT: Study protocol for a phase II/III, randomized, placebo-controlled, single blind study to evaluate the new hemostatic agent TT-173 in total knee arthroplasty

ClinicalTrials.gov identifier: NCT02687399. Registered the 9th of February 2016.